Role of the NMDA receptor in cognitive deficits, anxiety and depressive-like behavior in juvenile and adult mice after neonatal dexamethasone exposure

Neurobiology of Disease

Volumn 62, Issue , 2014, Pages 124-134

  Li, Su Xia ^a,b   Fujita, Yuko ^a   Zhang, Ji Chun ^a   Ren, Qian ^a   Ishima, Tamaki ^a   Wu, Jin ^a   Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

^b PEKING UNIVERSITY   (China)

Author keywords

Adult; Anxiety; Cognition; Depression; Dexamethasone; GluN2B subunit; Hydrocortisone; Juvenile; Neonatal; NMDA receptor

Indexed keywords

4 AMINOBUTYRIC ACID; 7 CHLORO 4 HYDROXY 3 (3 PHENOXYPHENYL) 2 QUINOLONE; CORTICOSTERONE; DEXAMETHASONE; DEXTRO SERINE; GLUTAMIC ACID; GLUTAMINE; GLYCINE; HYDROCORTISONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RO 63 1908; SERINE; UNCLASSIFIED DRUG;

ADULT ANIMAL; AMINO ACID BRAIN LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; BEHAVIOR DISORDER; COGNITIVE DEFECT; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DEPRESSION; DEXAMETHASONE SUPPRESSION TEST; FRONTAL CORTEX; HIPPOCAMPUS; JUVENILE ANIMAL; MOUSE; NEUROTRANSMISSION; NEWBORN; NONHUMAN; PRIORITY JOURNAL;

ADULT; ANXIETY; COGNITION; DEPRESSION; DEXAMETHASONE; GLUN2B SUBUNIT; HYDROCORTISONE; JUVENILE; NEONATAL; NMDA RECEPTOR;

AGE FACTORS; ANIMALS; ANIMALS, NEWBORN; ANXIETY; BRAIN CHEMISTRY; COGNITION DISORDERS; DEPRESSION; DEXAMETHASONE; FEMALE; FRONTAL LOBE; HIPPOCAMPUS; HYDROCORTISONE; MALE; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84885452649     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.09.004     Document Type: Article

References (61)

1. American Academy of Pediatrics AAP publications retired or reaffirmed, May 2004. Pediatrics 2006, 117:1846-1847.
2. Aoyama C., Santa T., Tsunoda M., Fukushima T., Kitada C., Imai K. A fully automated amino acid analyzer using NBD-F as a fluorescent derivatization reagent. Biomed. Chromatogr. 2004, 18:630-636.
3. Armstrong D.L., Penrice J., Bloomfield F.H., Knight D.B., Dezoete J.A., Harding J.E. Follow up of a randomised trial of two different courses of dexamethasone for preterm babies at risk of chronic lung disease. Arch. Dis. Child. Fetal Neonatal Ed. 2002, 86:F102-F107.
4. Barrington K.J. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr. 2001, 1:1-9.
5. Carroll B.J., Feinberg M., Greden J.F., Tarika J., Albala A.A., Haskett R.F., James N.M., Kronfol Z., Lohr N., Steiner M., de Vigne J.P., Young E. A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Arch. Gen. Psychiatry 1981, 38:15-22.
6. Collingridge G.L., Volianskis A., Bannister N., France G., Hanna L., Mercier M., Tidball P., Fang G., Irvine M.W., Costa B.M., Monaghan D.T., Bortolotto Z.A., Molnár E., Lodge D., Jane D.E. The NMDA receptor as a target for cognitive enhancement. Neuropharmacology 2013, 64:13-26.
7. Committee on Fetus Newborn Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 2002, 109:330-338.
8. Contestabile A. Roles of NMDA receptor activity and nitric oxide production in brain development. Brain Res. Brain Res. Rev. 2000, 32:476-509.
9. Engelmann M., Wotjak C.T., Landgraf R. Social discrimination procedure: an alternative method to investigate juvenile recognition abilities in rats. Physiol. Behav. 1995, 58:315-321.
10. Flagel S.B., Vazquez D.M., Watson S.J.J., Neal C.R. Effects of tapering neonatal dexamethasone on rat growth, neurodevelopment, and stress response. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2002, 282:R55-R63.
11. Fukushima T., Kawai J., Imai K., Toyo'oka T. Simultaneous determination of d- and l-serine in rat brain microdialysis sample using a column-switching HPLC with fluorimetric detection. Biomed. Chromatogr. 2004, 18:813-819.
12. Halliday H.L., Ehrenkranz R.A. Delayed (>3weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst. Rev. 2000, CD001145.
13. Halliday H.L., Ehrenkranz R.A. Early postnatal (<96hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst. Rev. 2000, CD001146.
14. Halliday H.L., Ehrenkranz R.A. Moderately early (7-14days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst. Rev. 2001, 1. (CD001144).
15. Hashimoto K. The NMDA receptor hypofunction hypothesis for schizophrenia and glycine modulatory sites on the NMDAreceptors as potential therapeutic drugs. Clin. Psychopharmacol. Neurosci. 2006, 4:3-10.
16. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res. Rev. 2009, 61:105-123.
17. Hashimoto K., Engberg G., Shimizu E., Nordin C., Lindstrom L.H., Iyo M. Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients. BMC Psychiatry 2005, 5:6.
18. Hashimoto K., Fujita Y., Horio M., Kunitachi S., Iyo M., Ferraris D., Tsukamoto T. Co-administration of a d-amino acid oxidase inhibitor potentiates the efficacy of d-serine in attenuating prepulse inhibition deficits after administration of dizocilpine. Biol. Psychiatry 2009, 65:1103-1106.
19. Hashimoto K., Fujita Y., Shimizu E., Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. Eur. J. Pharmacol. 2005, 519:114-117.
20. Hashimoto K., Ishima T., Fujita Y., Matsuo M., Kobashi T., Takahagi M., Tsukada H., Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711. Biol. Psychiatry 2008, 63:92-97.
21. Hashimoto K., Malchow B., Falkai P., Schmitt A. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur. Arch. Psychiatry Clin. Neurosci. 2013, 263:367-377.
22. Hashimoto K., Okamura N., Shimizu E., Iyo M. Glutamate hypothesis of schizophrenia and approach for possible therapeutic drugs. Curr. Med. Chem. CNS Agents 2004, 4:147-154.
23. Hashimoto K., Sawa A., Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol. Psychiatry 2007, 62:1310-1316.
24. Hashimoto K., Shimizu E., Lyo M. Dysfunction of glia-neuron communication in pathophysiology of schizophrenia. Curr. Psychiatry Rev. 2005, 1:151-163.
25. Heine V.M., Rowitch D.H. Hedgehog signaling has a protective effect in glucocorticoid-induced mouse neonatal brain injury through an 11betaHSD2-dependent mechanism. J. Clin. Invest. 2009, 119:267-277.
26. Horio M., Kohno M., Fujita Y., Ishima T., Inoue R., Mori H., Hashimoto K. Levels of d-serine in the brain and peripheral organs of serine racemase (Srr) knock-out mice. Neurochem. Int. 2011, 59:853-859.
27. Huang C.C., Lin H.R., Liang Y.C., Hsu K.S. Effects of neonatal corticosteroid treatment on hippocampal synaptic function. Pediatr. Res. 2007, 62:267-270.
28. Jones R., Wincott E., Elbourne D., Grant A. Controlled trial of dexamethasone in neonatal chronic lung disease: a 3-year follow-up. Pediatrics 1995, 96:897-906.
29. Kamphuis P.J., Croiset G., Bakker J.M., Van B.F., Van Ree J.M., Wiegant V.M. Neonatal dexamethasone treatment affects social behaviour of rats in later life. Neuropharmacology 2004, 47:461-474.
30. Kamphuis P.J., Gardoni F., Kamal A., Croiset G., Bakker J.M., Cattabeni F., Gispen W.H., van Bel F., Di Luca M., Wiegant V.M. Long-lasting effects of neonatal dexamethasone treatment on spatial learning and hippocampal synaptic plasticity: involvement of the NMDA receptor complex. FASEB J. 2003, 17:911-913.
31. Karemaker R., Heijnen C.J., Veen S., Baerts W., Samsom J., Visser G.H., Kavelaars A., van Doornen L.J., van Bel F. Differences in behavioral outcome and motor development at school age after neonatal treatment for chronic lung disease with dexamethasone versus hydrocortisone. Pediatr. Res. 2006, 60:745-750.
32. Kathol R.G., Jaeckle R.S., Lopez J.F., Meller W.H. Pathophysiology of HPA axis abnormalities in patients with major depression: an update. Am. J. Psychiatry 1989, 146:311-317.
33. Kreider M.L., Tate C.A., Cousins M.M., Oliver C.A., Seidler F.J., Slotkin T.A. Lasting effects of developmental dexamethasone treatment on neural cell number and size, synaptic activity, and cell signaling: critical periods of vulnerability, dose-effect relationships, regional targets, and sex selectivity. Neuropsychopharmacology 2006, 31:12-35.
34. Lewis D.A., Curley A.A., Glausier J.R., Volk D.W. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci. 2012, 35:57-67.
35. Lewis D.A., Hashimoto T., Volk D.W. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 2005, 6:312-324.
36. Lodygensky G.A., Rademaker K., Zimine S., Gex-Fabry M., Lieftink A.F., Lazeyras F., Groenendaal F., de Vries L.S., Huppi P.S. Structural and functional brain development after hydrocortisone treatment for neonatal chronic lung disease. Pediatrics 2005, 116:1-7.
37. Lopez-Duran N.L., Kovacs M., George C.J. Hypothalamic-pituitary-adrenal axis dysregulation in depressed children and adolescents: a meta-analysis. Psychoneuroendocrinology 2009, 34:1272-1283.
38. Mammel M.C., Green T.P., Johnson D.E., Thompson T.R. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet 1983, 1:1356-1358.
39. Neal C.R., Weidemann G., Kabbaj M., Vazquez D.M. Effect of neonatal dexamethasone exposure on growth and neurological development in the adult rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004, 287:R375-385.
40. Needelman H., Hoskoppal A., Roberts H., Evans M., Bodensteiner J.B. The effect of hydrocortisone on neurodevelopmental outcome in premature infants less than 29weeks' gestation. J. Child Neurol. 2010, 25:448-452.
41. O'Shea T.M., Kothadia J.M., Klinepeter K.L., Goldstein D.J., Jackson B., Dillard R.G. Follow-up of preterm infants treated with dexamethasone for chronic lung disease. Am. J. Dis. Child. 1993, 147:658-661.
42. O'Shea T.M., Kothadia J.M., Klinepeter K.L., Goldstein D.J., Jackson B.G., Weaver R.G., Dillard R.G. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics 1999, 104:15-21.
43. Pariante C.M., Miller A.H. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol. Psychiatry 2001, 49:391-404.
44. Popik P., van Ree J.M. Neurohypophyseal peptides and social recognition in rats. Prog. Brain Res. 1998, 119:415-436.
45. Rademaker K.J., de Vries L.S., Uiterwaal C.S.P.M., Groenendaal F., Grobbee D.E., van Bel F. Postnatal hydrocortisone treatment for chronic lung disease in the preterm newborn and long-term neurodevelopmental follow-up. Arch. Dis. Child. Fetal Neonatal Ed. 2008, 39:F58-F63.
46. Romagnoli C., Zecca E., Luciano R., Torrioli G., Tortorolo G. A three year follow up of preterm infants after moderately early treatment with dexamethasone. Arch. Dis. Child. Fetal Neonatal Ed. 2002, 87:F55-F58.
47. Sanz-Clemente A., Nicoll R.A., Roche K.W. Diversity in NMDA receptor composition: many regukators, many consequences. Neuroscientist 2013, 19:62-75.
48. Shinwell E.S., Karplus M., Reich D., Weintraub Z., Blazer S., Bader D., Yurman S., Dolfin T., Kogan A., Dollberg S., Arbel E., Goldberg M., Gur I., Naor N., Sirota L., Mogilner S., Zaritsky A., Barak M., Gottfried E. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch. Dis. Child. Fetal Neonatal Ed. 2000, 83:177-181.
49. Stark A.R., Carlo W.A., Tyson J.E., Papile L.A., Wright L.L., Shankaran S., Donovan E.F., Oh W., Bauer C.R., Saha S., Poole W.K., Stoll B.J. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N. Engl. J. Med. 2001, 344:95-101.
50. Tokita K., Fujita Y., Yamaji T., Hashimoto K. Depressive-like behavior in adrenocorticotropic hormone-treated rats blocked by memantine. Pharmacol. Biochem. Behav. 2012, 102:329-334.
51. Tokita K., Yamaji T., Hashimoto K. Roles of glutamate signaling in preclinical and/or mechanistic models of depression. Pharmacol. Biochem. Behav. 2012, 100:688-704.
52. van der Heide-Jalving M., Kamphuis P.J.G.H., van der Laan M.J., Bakker J.M., Wiegant V.M., Heijnen C.J., Veen S., van Bel F. Short- and long-term effects of neonatal glucocorticoid therapy: is hydrocortisone an alternative to dexamethasone?. Acta Paediatr. 2003, 92:827-835.
53. Watterberg K. Evidence-based neonatal pharmacotherapy: postnatal corticosteroids. Clin. Perinatol. 2012, 39:47-59.
54. Watterberg K.L. Policy statement - postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Pediatrics 2010, 126:800-808.
55. Watterberg K.L., Shaffer M.L., Mishefske M.J., Leach C.L., Mammel M.C., Couser R.J., Abbasi S., Cole C.H., Aucott S.W., Thilo E.H., Rozycki H.J., Lacy C.B. Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. Pediatrics 2007, 120:40-48.
56. Wenzel A., Fritschy J.M., Mohler H., Benke D. NMDA receptor heterogeneity during postnatal development of the rat brain: differential expression of the NR2A, NR2B, and NR2C subunit proteins. J. Neurochem. 1997, 68:469-478.
57. Wolosker H. NMDA receptor regulation by d-serine: new findings and perspectives. Mol. Neurobiol. 2007, 36:152-164.
58. Yeh T.F., Lin Y.J., Lin H.C., Huang C.C., Hsieh W.S., Lin C.H., Tsai C.H. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N. Engl. J. Med. 2004, 350:1304-1313.
59. Zhang L., Shirayama Y., Iyo M., Hashimoto K. Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology 2007, 32:2004-2010.
60. Zhong J., Carrozza D.P., Williams K., Pritchett D.B., Molinoff P.B. Expression of mRNAs encoding subunits of the NMDA receptor in developing rat brain. J. Neurochem. 1995, 64:531-539.
61. Zorumski C.F., Izumi Y. NMDA receptors and metaplasticity: mechanisms and possible roles in neuropsychiatric disorders. Neurosci. Biobehav. Rev. 2012, 36:989-1000.